company background image
KRKG logo

Krka d. d LJSE:KRKG Stock Report

Last Price

€184.00

Market Cap

€5.6b

7D

-1.1%

1Y

45.5%

Updated

29 May, 2025

Data

Company Financials +

Krka, d. d.

LJSE:KRKG Stock Report

Market Cap: €5.6b

KRKG Stock Overview

A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details

KRKG fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends5/6

Rewards

Trading at 24% below our estimate of its fair value

Earnings are forecast to grow 3.42% per year

Earnings grew by 26.7% over the past year

Pays a reliable dividend of 4.5%

Risk Analysis

No risks detected for KRKG from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Krka, d. d. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Krka d. d
Historical stock prices
Current Share Price€184.00
52 Week High€187.50
52 Week Low€126.00
Beta0.44
1 Month Change6.05%
3 Month Change9.20%
1 Year Change45.45%
3 Year Change105.36%
5 Year Change119.05%
Change since IPO2,219.87%

Recent News & Updates

Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's

May 18
Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's

Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 28% Undervaluation?

May 08
Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 28% Undervaluation?

Recent updates

Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's

May 18
Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's

Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 28% Undervaluation?

May 08
Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 28% Undervaluation?

Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?

Apr 01
Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?

Is Krka, d. d. (LJSE:KRKG) Trading At A 32% Discount?

Jan 14
Is Krka, d. d. (LJSE:KRKG) Trading At A 32% Discount?

Krka, d. d.'s (LJSE:KRKG) Share Price Could Signal Some Risk

Dec 13
Krka, d. d.'s (LJSE:KRKG) Share Price Could Signal Some Risk

Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit

Aug 27
Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit

Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?

Aug 09
Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?

Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year

Jul 22
Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year

Krka d. d (LJSE:KRKG) Will Pay A Larger Dividend Than Last Year At €7.50

Jun 11
Krka d. d (LJSE:KRKG) Will Pay A Larger Dividend Than Last Year At €7.50

Shareholder Returns

KRKGSI PharmaceuticalsSI Market
7D-1.1%-0.7%0.9%
1Y45.5%-16.9%40.6%

Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned -16.9% over the past year.

Return vs Market: KRKG exceeded the SI Market which returned 40.6% over the past year.

Price Volatility

Is KRKG's price volatile compared to industry and market?
KRKG volatility
KRKG Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.3%
10% most volatile stocks in SI Market4.7%
10% least volatile stocks in SI Market3.7%

Stable Share Price: KRKG has not had significant price volatility in the past 3 months compared to the SI market.

Volatility Over Time: KRKG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195412,925Jože Colaricwww.krka.biz

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, infections, oncology, and other diseases. It provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.

Krka, d. d. Fundamentals Summary

How do Krka d. d's earnings and revenue compare to its market cap?
KRKG fundamental statistics
Market cap€5.60b
Earnings (TTM)€410.29m
Revenue (TTM)€1.95b
13.7x
P/E Ratio
2.9x
P/S Ratio

Is KRKG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KRKG income statement (TTM)
Revenue€1.95b
Cost of Revenue€827.15m
Gross Profit€1.12b
Other Expenses€708.07m
Earnings€410.29m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 24, 2025

Earnings per share (EPS)13.42
Gross Margin57.48%
Net Profit Margin21.09%
Debt/Equity Ratio0%

How did KRKG perform over the long term?

See historical performance and comparison

Dividends

4.5%
Current Dividend Yield
62%
Payout Ratio

Does KRKG pay a reliable dividends?

See KRKG dividend history and benchmarks
When do you need to buy KRKG by to receive an upcoming dividend?
Krka d. d dividend dates
Ex Dividend DateJul 22 2025
Dividend Pay DateJul 24 2025
Days until Ex dividend53 days
Days until Dividend pay date55 days

Does KRKG pay a reliable dividends?

See KRKG dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 21:10
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krka, d. d. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saso StanovnikAlta Invest
Simon MatherBarclays
Stephane SumarBNP Paribas Exane